MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurjpc/zwag425

Медицинская библиотека · European journal of preventive cardiology · 2026

Lipoprotein(a) distributions and trial eligibility thresholds for Lp(a)-lowering therapies in the general population: The Rotterdam Study.

Hermans Gaia, Bos Daniel, Kavousi Maryam, Ikram M Arfan, Sijbrands Eric J G, Wolters Frank J, van Lennep Jeanine E Roeters, Leening Maarten J G

СтатьяПеревод в очереди

Аннотация

AIMS: General population distributions of lipoprotein(a) (Lp(a)) are well-characterized. However, less is known about its distributions and associated event rates within high-risk populations, including individuals with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and varying levels of subclinical atherosclerosis and calcific aortic valve disease. Yet, such insights will facilitate clinical implementation of Lp(a) testing and enhance the design of clinical trials with Lp(a)-lowering agents.

METHODS

Data from 5,129 participants in the population-based Rotterdam Study were used to assess Lp(a) distributions, prevalence of Lp(a) levels exceeding thresholds used in ongoing trials (i.e. >150, >175, and >200 nmol/L), accompanying numbers needed to screen (NNS), and major adverse cardiovascular event (MACE) rates across high-risk groups.

RESULTS

Lp(a) distributions were right skewed across all groups. Among participants with ASCVD, 13.5% (11.9-15.3%) had Lp(a) >150 nmol/L and 6.5% (5.3-7.8%) had >200 nmol/L, with corresponding NNS 7.4 and 15.4. Similar distributions were observed between participants with coronary artery calcium (CAC) score >300 and participants with coronary heart disease (CHD). Prevalence in participants with aortic valve calcification (AVC) scores >300 was double that of the general population: 20.2% (13.0-27.4) at >150 nmol/L and 11.8% (6.6-19.0) at >200 nmol/L, with the lowest NNS across all groups (5.0-8.5). MACE rates varied by group and increased progressively with higher Lp(a) thresholds.

CONCLUSIONS

Lp(a) distributions and MACE rates substantially vary across high-risk groups in the general population. These findings can facilitate design and recruitment strategies of studies with emerging Lp(a)-lowering therapies, while also aiding in identification of populations who may benefit from such therapies.

Для цитирования: Hermans Gaia, Bos Daniel, Kavousi Maryam, Ikram M Arfan, Sijbrands Eric J G, Wolters Frank J, van Lennep Jeanine E Roeters, Leening Maarten J G. Lipoprotein(a) distributions and trial eligibility thresholds for Lp(a)-lowering therapies in the general population: The Rotterdam Study.. European journal of preventive cardiology. 2026. DOI: 10.1093/eurjpc/zwag425.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.